CONFIDENTIAL TREATMENT REQUESTED First Amendment to the Research and Development Collaboration and License Agreement
Exhibit 4.4
CONFIDENTIAL TREATMENT REQUESTED
First Amendment to the
This is the first Amendment (hereinafter “Amendment”) to the Research and Development Collaboration and License Agreement between Bayer Pharma AG, a company formed under the laws of Germany, having a
place of business at Xxxxxxxxxxxxxx 000, 00000 Xxxxxx, Xxxxxxx (hereinafter: “BAYER”) and Compugen Ltd, a company formed under the laws of Israel, having a place of business at 00 Xxxxxxx Xxxxx Xxxxxx, Xxx Xxxx 00000, Xxxxxx (hereinafter: “Compugen”)
effective as of 5 August 2013 (hereinafter: the “Agreement”).
WHEREAS The parties wish to amend the exhibit specifying the Bayer Development Process.
NOW THEREFORE IT IS AGREED AS FOLLOWS:
| 1. | The parties agree to replace Exhibit 1.3 of the Agreement by Exhibit 1.3 attached to this Amendment, describing the “Bayer Development Process”. |
| 2. | This Amendment shall become retroactively effective as of 5 August 2013. |
| 3. | All capitalized terms used herein shall have the meaning set forth in the Agreement. Except as expressly amended pursuant to this Amendment, all other terms and conditions of the Agreement shall remain in force unchanged and apply to this Amendment. |
Certain information in this document, marked by [***], has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K under
the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
CONFIDENTIAL TREATMENT REQUESTED
|
SIGNED for and on behalf of
Bayer Pharma AG
|
SIGNED for and on behalf of
|
|
Date: February 3, 2014
|
Date: February 5, 2014
|
|
/s/ Xx. Xxxx Xxxxxxxxxxx
Xx. Xxxx Xxxxxxxxxxx
(Head GDD - TRG Oncology / Gynecological Therapy)
|
/s/ Xxxx Xxxxx-Xxxxx
President and CEO
|
|
/s/ Xx. Xxxxxxx Xxxxx
Xx. Xxxxxxx Xxxxx
(Head GDD-ONC/GT-IABDC)
|
Certain information in this document, marked by [***], has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act
of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
2
CONFIDENTIAL TREATMENT REQUESTED
Exhibit 1.3: Bayer Development Process
[***, 3 pages]
Certain information in this document, marked by [***], has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K under
the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
3
